Kardigan

2 articles

Kardigan Surges in Nasdaq Debut After Upsized $400 Million IPO

Kardigan, a biotech developer of cardiovascular therapies, surged over 30% in its Nasdaq debut following a $400 million IPO. The funding will support late-stage clinical trials for experimental heart

reuters · 2026-06-18 09:49

Heart drug developer Kardigan targets $1.4 billion valuation in US IPO

Kardigan, a clinical-stage biotech focused on cardiovascular precision medicines, aims for a $1.4 billion valuation in its US IPO while raising up to $373.3 million to advance three late-stage experim

reuters · 2026-06-11 03:33